Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, has entered into a joint venture with Virginia Cancer Specialists (VCS). Dr. Alex Spira of VCS sought to expand the clinic’s Phase I and developmental therapeutics cancer research program and bring the latest in new agents and anticancer treatments to its Research Institute. NEXT Oncology has relationships …
Medications deemed essential to breast cancer prevention
By: Richard Gawel From: healio.com Medication can play an essential role in breast cancer prevention, Holly J. Pederson, MD, director of medical breast services at the Cleveland Clinic, said during the NAMS Annual Meeting. “My objectives… are to identify women who will benefit most from risk-reducing medications, to recognize the importance of comorbid conditions and the timing of therapy and …
My Personal Breast Cancer Awareness Purpose
View PostDefence Therapeutics embark on next stage of breast cancer treatment development
From: healtheuropa.eu In a groundbreaking development, pioneering biotechnology company Defence Therapeutics has announced today it will be performing the final necessary studies before entering a Phase 1 trial for its innovative AccuTOX breast cancer treatment. AccuTOX is one of Defence Therapeutics‘ premier candidates for effective breast cancer treatment and is comprised of the company’s cutting-edge AccumTM technology platform, which was …
C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities
Source: Accuray Incorporated From: prnewswire.com C-RAD AB (NASDAQ Stockholm: CRAD B) and Accuray Incorporated (NASDAQ: ARAY) announced today they have signed an agreement designed to enhance the Accuray Radixact® System’s ability to treat breast cancer. The companies will partner to provide customers with a solution for deep inspiration breath hold (DIBH)* using the C-RAD Catalyst+ HD and Radixact System. DIBH …
Clinical Challenges: When to Start End-of-Life Care in Metastatic Breast Cancer
By: Leah Lawrence From: medpagetoday.com Breast cancer remains the second leading cause of cancer death among women in the U.S. Although treatments for metastatic breast cancer — whether a new diagnosis or recurrent disease — have improved in recent years, metastatic disease remains incurable, explained Dawn L. Hershman, MD, MS, director of breast oncology at the Herbert Irving Comprehensive Cancer …
How breast cancer treatments can affect the immune system
By: Metro Creative Services From: crescent-news.com Treatment for breast cancer is highly effective. Five-year survival rates for breast cancer have increased dramatically in recent decades, and much of that success can be credited to cancer researchers and campaigns designed to inform women about the importance of screenings. Breast cancer is highly treatable, but treatment typically leads to some unwanted side …
Clinical dilemmas in breast cancer patients solved by newly approved PET imaging agent
Source: Society of Nuclear Medicine and Molecular Imaging From: news-medical.net A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise. The 18F-FES PET scan-;approved by the U.S. Food and Drug Administration in 2020-;was shown to solve 87 percent of dilemmas, providing physicians with information for personalized treatment decision-making. This research was …
MRIs found to be cost effective for detecting breast cancer for women with very dense breasts
Source: Oxford University Press USA From: news-medical.net A new paper in the Journal of the National Cancer Institute, published by Oxford University Press, indicates that MRIs are cost effective for detecting breast cancer for women with very dense breasts detected by mammography. About 10% of women have extremely dense breasts, and current mammography screening guidelines do not recommend additional imaging …
Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival
Source: Inbiomotion From: prnewswire.com – Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis – Data published in Journal of National Cancer Institute, Cancer Spectrum – MAF-negative status of patients who were …